Omni Bio Pharmaceutical (OTCMKTS:OMBP) Trading Down 49%

Omni Bio Pharmaceutical Inc (OTCMKTS:OMBP)’s share price was down 49% during mid-day trading on Friday . The stock traded as low as $0.01 and last traded at $0.01. Approximately 4,500 shares were traded during trading, an increase of 7% from the average daily volume of 4,187 shares. The stock had previously closed at $0.02.

The stock has a 50-day simple moving average of $0.01.

About Omni Bio Pharmaceutical (OTCMKTS:OMBP)

Omni Bio Pharmaceutical, Inc operates as a biopharmaceutical company in the United States. It holds a license to use patent for the treatment of diabetes using plasma-derived alpha-1 antitrypsin (p-AAT), a protein that is purified from human blood. The company also holds licenses for the use of patents and patent applications covering the use of p-AAT in the treatment of cellular transplantation and graft rejection, radiation protection, bacterial and viral diseases, myocardial remodeling, and inflammatory bowel disease indications.

Read More: Balanced Fund

Receive News & Ratings for Omni Bio Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omni Bio Pharmaceutical and related companies with's FREE daily email newsletter.